--- title: "GB-115: Dosing & Vendor Prices — BodyHackGuide" description: "GB-115: dosing protocols, mechanism & side effects. Compare 1 verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "GB-115" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "GB-115", "description": "GB-115 is a synthetic dipeptide, N-(6-phenylhexanoyl)glycyl-L-tryptophan amide, designed at the Zakusov Research Institute of Pharmacology in Moscow. It belongs to a Russian program that builds short peptides as topological analogs of the active fragment of a regulatory peptide, the same approach that produced noopept and dilept. GB-115 is a retro-analog of the beta turn of cholecystokinin tetrapeptide, and conformational work identified a beta II turn as the structure responsible for its activity (PMID: 17886432, PMID: 24397028, PMID: 30295186). The stereochemistry matters. In the original series of analogs, the L-tryptophan compounds were anxiolytic and the D-tryptophan compounds anxiogenic, and GB-115 was selected as the L-tryptophan lead (PMID: 17886432). It acts as a low-affinity blocker of central cholecystokinin receptors. In mice and rats, activating cholecystokinin tetrapeptide type 2 receptors abolished its anti-anxiety effect and the compound prevented cholecystokinin-induced anxiety, while the alpha2 adrenoceptor antagonist yohimbine did not interact with it, which the authors read as a shared pharmacological target with cholecystokinin tetrapeptide (PMID: 23113301). The animal file is broad. Oral administration produced anxiolytic effects in outbred mice, BALB/c mice and outbred rats in open field and elevated plus maze tests (PMID: 24130989), antidepressant-like reduction of immobility in the forced swim test that was weaker than amitriptyline (PMID: 21476266), reduced average daily ethanol consumption and the alcohol deprivation effect in high-emotionality MR rats (PMID: 27590755), and reduced anxiety during benzodiazepine withdrawal in outbred and inbred rats (PMID: 22238979). A repeated theme is that the effect depends on the animal phenotype: strains with a passive response to emotional stress respond differently from active ones (PMID: 12910281). A study in four male rhesus monkeys under individual caging reported reduced stress-related behavior and a lower cortisol to DHEA-S ratio, comparable to phenazepam (PMID: 39847298). Safety and dependence data in animals are more complete than for most compounds sold this way. A preclinical package found no deaths after single oral administration at up to 6000 mg/kg in mice and 3500 mg/kg in rats, no irreversible organ changes over six months of oral administration in rats and rabbits, and no allergenic, immunotoxic or mutagenic activity and no effect on reproduction or offspring development (PMID: 20726348). After 30 days of daily administration to rats, stopping the compound produced no anxiety, aggression or convulsive signs, in contrast to diazepam withdrawal in the same experiment (PMID: 21899090). Oral bioavailability in rats was low at 4.65 percent for the crystalline substance, which is why later work compared micronized and reformulated versions (PMID: 18457023, PMID: 27017703). Human evidence is Russian and mostly unpublished in indexed journals. Thirty-one patients with generalized anxiety disorder were treated for 21 days, an effective daily dose was identified, and the authors described a fast anxiolytic effect with a stimulating component and favorable changes in attention parameters and reaction time (PMID: 31626171). That report does not describe randomization, blinding or a placebo arm in its published abstract. The Russian trial registry records that study as an open phase IIa pilot, followed by a double-blind, randomized, placebo-controlled multicenter trial sponsored by Valenta Pharm from April 2021 to December 2022, and the Russian product label cites two placebo-controlled trials of 168 and 220 patients, none of which is indexed in PubMed. On 29 December 2023 GB-115 was registered in Russia as the prescription tablet Rankvilon for anxiety states in neurasthenia and adjustment disorders. It has no FDA or EMA authorization, and the aerosol spray sold on the research chemical market is not the registered tablet and is a research-use-only compound in the US market.", "url": "https://www.bodyhackguide.co/compound/gb-115", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "59.99", "highPrice": "59.99", "priceCurrency": "USD", "offerCount": "1", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "59.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/gb-115-aerosol-spray/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "GB-115", "description": "GB-115 is a synthetic dipeptide, N-(6-phenylhexanoyl)glycyl-L-tryptophan amide, designed at the Zakusov Research Institute of Pharmacology in Moscow. It belongs to a Russian program that builds short peptides as topological analogs of the active fragment of a regulatory peptide, the same approach that produced noopept and dilept. GB-115 is a retro-analog of the beta turn of cholecystokinin tetrapeptide, and conformational work identified a beta II turn as the structure responsible for its activity (PMID: 17886432, PMID: 24397028, PMID: 30295186). The stereochemistry matters. In the original series of analogs, the L-tryptophan compounds were anxiolytic and the D-tryptophan compounds anxiogenic, and GB-115 was selected as the L-tryptophan lead (PMID: 17886432). It acts as a low-affinity blocker of central cholecystokinin receptors. In mice and rats, activating cholecystokinin tetrapeptide type 2 receptors abolished its anti-anxiety effect and the compound prevented cholecystokinin-induced anxiety, while the alpha2 adrenoceptor antagonist yohimbine did not interact with it, which the authors read as a shared pharmacological target with cholecystokinin tetrapeptide (PMID: 23113301). The animal file is broad. Oral administration produced anxiolytic effects in outbred mice, BALB/c mice and outbred rats in open field and elevated plus maze tests (PMID: 24130989), antidepressant-like reduction of immobility in the forced swim test that was weaker than amitriptyline (PMID: 21476266), reduced average daily ethanol consumption and the alcohol deprivation effect in high-emotionality MR rats (PMID: 27590755), and reduced anxiety during benzodiazepine withdrawal in outbred and inbred rats (PMID: 22238979). A repeated theme is that the effect depends on the animal phenotype: strains with a passive response to emotional stress respond differently from active ones (PMID: 12910281). A study in four male rhesus monkeys under individual caging reported reduced stress-related behavior and a lower cortisol to DHEA-S ratio, comparable to phenazepam (PMID: 39847298). Safety and dependence data in animals are more complete than for most compounds sold this way. A preclinical package found no deaths after single oral administration at up to 6000 mg/kg in mice and 3500 mg/kg in rats, no irreversible organ changes over six months of oral administration in rats and rabbits, and no allergenic, immunotoxic or mutagenic activity and no effect on reproduction or offspring development (PMID: 20726348). After 30 days of daily administration to rats, stopping the compound produced no anxiety, aggression or convulsive signs, in contrast to diazepam withdrawal in the same experiment (PMID: 21899090). Oral bioavailability in rats was low at 4.65 percent for the crystalline substance, which is why later work compared micronized and reformulated versions (PMID: 18457023, PMID: 27017703). Human evidence is Russian and mostly unpublished in indexed journals. Thirty-one patients with generalized anxiety disorder were treated for 21 days, an effective daily dose was identified, and the authors described a fast anxiolytic effect with a stimulating component and favorable changes in attention parameters and reaction time (PMID: 31626171). That report does not describe randomization, blinding or a placebo arm in its published abstract. The Russian trial registry records that study as an open phase IIa pilot, followed by a double-blind, randomized, placebo-controlled multicenter trial sponsored by Valenta Pharm from April 2021 to December 2022, and the Russian product label cites two placebo-controlled trials of 168 and 220 patients, none of which is indexed in PubMed. On 29 December 2023 GB-115 was registered in Russia as the prescription tablet Rankvilon for anxiety states in neurasthenia and adjustment disorders. It has no FDA or EMA authorization, and the aerosol spray sold on the research chemical market is not the registered tablet and is a research-use-only compound in the US market.", "lastReviewed": "2026-09-07T04:46:53.766Z", "url": "https://www.bodyhackguide.co/compound/gb-115", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "GB-115", "alternateName": [ "GB115", "Rankvilon", "N-(6-phenylhexanoyl)glycyl-L-tryptophanamide", "N-(1-oxo-6-phenylhexyl)glycyl-L-tryptophanamide", "Ph(CH2)5CO-Gly-L-Trp-NH2", "CCK-4 retrodipeptide analog" ], "description": "GB-115 is a synthetic dipeptide, N-(6-phenylhexanoyl)glycyl-L-tryptophan amide, designed at the Zakusov Research Institute of Pharmacology in Moscow. It belongs to a Russian program that builds short peptides as topological analogs of the active fragment of a regulatory peptide, the same approach that produced noopept and dilept. GB-115 is a retro-analog of the beta turn of cholecystokinin tetrapeptide, and conformational work identified a beta II turn as the structure responsible for its activity (PMID: 17886432, PMID: 24397028, PMID: 30295186). The stereochemistry matters. In the original series of analogs, the L-tryptophan compounds were anxiolytic and the D-tryptophan compounds anxiogenic, and GB-115 was selected as the L-tryptophan lead (PMID: 17886432). It acts as a low-affinity blocker of central cholecystokinin receptors. In mice and rats, activating cholecystokinin tetrapeptide type 2 receptors abolished its anti-anxiety effect and the compound prevented cholecystokinin-induced anxiety, while the alpha2 adrenoceptor antagonist yohimbine did not interact with it, which the authors read as a shared pharmacological target with cholecystokinin tetrapeptide (PMID: 23113301). The animal file is broad. Oral administration produced anxiolytic effects in outbred mice, BALB/c mice and outbred rats in open field and elevated plus maze tests (PMID: 24130989), antidepressant-like reduction of immobility in the forced swim test that was weaker than amitriptyline (PMID: 21476266), reduced average daily ethanol consumption and the alcohol deprivation effect in high-emotionality MR rats (PMID: 27590755), and reduced anxiety during benzodiazepine withdrawal in outbred and inbred rats (PMID: 22238979). A repeated theme is that the effect depends on the animal phenotype: strains with a passive response to emotional stress respond differently from active ones (PMID: 12910281). A study in four male rhesus monkeys under individual caging reported reduced stress-related behavior and a lower cortisol to DHEA-S ratio, comparable to phenazepam (PMID: 39847298). Safety and dependence data in animals are more complete than for most compounds sold this way. A preclinical package found no deaths after single oral administration at up to 6000 mg/kg in mice and 3500 mg/kg in rats, no irreversible organ changes over six months of oral administration in rats and rabbits, and no allergenic, immunotoxic or mutagenic activity and no effect on reproduction or offspring development (PMID: 20726348). After 30 days of daily administration to rats, stopping the compound produced no anxiety, aggression or convulsive signs, in contrast to diazepam withdrawal in the same experiment (PMID: 21899090). Oral bioavailability in rats was low at 4.65 percent for the crystalline substance, which is why later work compared micronized and reformulated versions (PMID: 18457023, PMID: 27017703). Human evidence is Russian and mostly unpublished in indexed journals. Thirty-one patients with generalized anxiety disorder were treated for 21 days, an effective daily dose was identified, and the authors described a fast anxiolytic effect with a stimulating component and favorable changes in attention parameters and reaction time (PMID: 31626171). That report does not describe randomization, blinding or a placebo arm in its published abstract. The Russian trial registry records that study as an open phase IIa pilot, followed by a double-blind, randomized, placebo-controlled multicenter trial sponsored by Valenta Pharm from April 2021 to December 2022, and the Russian product label cites two placebo-controlled trials of 168 and 220 patients, none of which is indexed in PubMed. On 29 December 2023 GB-115 was registered in Russia as the prescription tablet Rankvilon for anxiety states in neurasthenia and adjustment disorders. It has no FDA or EMA authorization, and the aerosol spray sold on the research chemical market is not the registered tablet and is a research-use-only compound in the US market.", "activeIngredient": "GB-115", "administrationRoute": "Oral, Intraperitoneal injection (animal studies), Aerosol spray (form sold on the research chemical market)", "mechanismOfAction": "GB-115 was designed as a retro-dipeptide analog of the beta turn of cholecystokinin tetrapeptide and acts as a low-affinity blocker of central cholecystokinin receptors (PMID: 17886432, PMID: 30295186). In mice and rats, activation of cholecystokinin tetrapeptide type 2 receptors abolished its anti-anxiety effect and the compound prevented cholecystokinin-induced anxiety, while the alpha2 adrenoceptor antagonist yohimbine did not modulate its effects, which the authors read as a shared pharmacological target with cholecystokinin tetrapeptide (PMID: 23113301). Nuclear magnetic resonance and structure-activity work on sterically restricted analogs identified a beta II turn as the biologically active conformation (PMID: 24397028). Its antinociceptive effect in mice is only partly reversed by naloxone, pointing to a secondary interaction with spinal opioid mechanisms alongside the cholecystokinin action (PMID: 22977846).", "dosageForm": "nasal_spray", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is GB-115 used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "GB-115 is a synthetic dipeptide, N-(6-phenylhexanoyl)glycyl-L-tryptophan amide, designed at the Zakusov Research Institute of Pharmacology in Moscow. It belongs to a Russian program that builds short peptides as topological analogs of the active fragment of a regulatory peptide, the same approach that produced noopept and dilept. GB-115 is a retro-analog of the beta turn of cholecystokinin tetrapeptide, and conformational work identified a beta II turn as the structure responsible for its activity (PMID: 17886432, PMID: 24397028, PMID: 30295186). The stereochemistry matters. In the original series of analogs, the L-tryptophan compounds were anxiolytic and the D-tryptophan compounds anxiogenic, and GB-115 was selected as the L-tryptophan lead (PMID: 17886432). It acts as a low-affinity blocker of central cholecystokinin receptors. In mice and rats, activating cholecystokinin tetrapeptide type 2 receptors abolished its anti-anxiety effect and the compound prevented cholecystokinin-induced anxiety, while the alpha2 adrenoceptor antagonist yohimbine did not interact with it, which the authors read as a shared pharmacological target with cholecystokinin tetrapeptide (PMID: 23113301). The animal file is broad. Oral administration produced anxiolytic effects in outbred mice, BALB/c mice and outbred rats in open field and elevated plus maze tests (PMID: 24130989), antidepressant-like reduction of immobility in the forced swim test that was weaker than amitriptyline (PMID: 21476266), reduced average daily ethanol consumption and the alcohol deprivation effect in high-emotionality MR rats (PMID: 27590755), and reduced anxiety during benzodiazepine withdrawal in outbred and inbred rats (PMID: 22238979). A repeated theme is that the effect depends on the animal phenotype: strains with a passive response to emotional stress respond differently from active ones (PMID: 12910281). A study in four male rhesus monkeys under individual caging reported reduced stress-related behavior and a lower cortisol to DHEA-S ratio, comparable to phenazepam (PMID: 39847298). Safety and dependence data in animals are more complete than for most compounds sold this way. A preclinical package found no deaths after single oral administration at up to 6000 mg/kg in mice and 3500 mg/kg in rats, no irreversible organ changes over six months of oral administration in rats and rabbits, and no allergenic, immunotoxic or mutagenic activity and no effect on reproduction or offspring development (PMID: 20726348). After 30 days of daily administration to rats, stopping the compound produced no anxiety, aggression or convulsive signs, in contrast to diazepam withdrawal in the same experiment (PMID: 21899090). Oral bioavailability in rats was low at 4.65 percent for the crystalline substance, which is why later work compared micronized and reformulated versions (PMID: 18457023, PMID: 27017703). Human evidence is Russian and mostly unpublished in indexed journals. Thirty-one patients with generalized anxiety disorder were treated for 21 days, an effective daily dose was identified, and the authors described a fast anxiolytic effect with a stimulating component and favorable changes in attention parameters and reaction time (PMID: 31626171). That report does not describe randomization, blinding or a placebo arm in its published abstract. The Russian trial registry records that study as an open phase IIa pilot, followed by a double-blind, randomized, placebo-controlled multicenter trial sponsored by Valenta Pharm from April 2021 to December 2022, and the Russian product label cites two placebo-controlled trials of 168 and 220 patients, none of which is indexed in PubMed. On 29 December 2023 GB-115 was registered in Russia as the prescription tablet Rankvilon for anxiety states in neurasthenia and adjustment disorders. It has no FDA or EMA authorization, and the aerosol spray sold on the research chemical market is not the registered tablet and is a research-use-only compound in the US market." } }, { "@type": "Question", "name": "What forms does GB-115 come in?", "acceptedAnswer": { "@type": "Answer", "text": "GB-115 is available in nasal_spray form." } }, { "@type": "Question", "name": "How much does GB-115 cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $59.99 across 1 verified vendor." } }, { "@type": "Question", "name": "How do I compare GB-115 vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Fgb-115) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. GB-115 [Where to buy GB-115](/buy/gb-115) [GB-115 coupon codes](/coupons/gb-115) [GB-115 protocol](/protocol/gb-115) [Alternatives to GB-115](/alternatives-to/gb-115) [GB-115 side effects](/side-effects/gb-115) 1. [Home](/) 3. [Compounds](/compare) 5. GB-115 ![GB-115 molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # GB-115 Nootropics Approved (Russia) Download PDF Also known as: GB115, Rankvilon, N-(6-phenylhexanoyl)glycyl-L-tryptophanamide, N-(1-oxo-6-phenylhexyl)glycyl-L-tryptophanamide, Ph(CH2)5CO-Gly-L-Trp-NH2, CCK-4 retrodipeptide analog GB-115 is a synthetic dipeptide, N-(6-phenylhexanoyl)glycyl-L-tryptophan amide, designed at the Zakusov Research Institute of Pharmacology in Moscow. It belongs to a Russian program that builds short peptides as topological analogs of the active fragment of a regulatory peptide, the same approach that produced noopept and dilept. Half-Life: Not established in humans; the published rat pharmacokinetic work reported an absolute oral bioavailability of 4.65 percent for the crystalline substance and did not report a terminal half-life (PMID: 18457023) Route: Oral, Intraperitoneal injection (animal studies), Aerosol spray (form sold on the research chemical market) MW: 434.5 g/mol CAS: 678996-63-9 Last reviewed: Sep 7, 2026 [ Nootropics Category ](/wiki#cat-nootropics) Approved (Russia) Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices1 Related ## Overview ### Best Price Available ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $59.99 10 mL aerosol spray · nasal\_spray [Buy Now](https://disguisedalpha.com/product/gb-115-aerosol-spray/?coupon=reddit) Compare 1 vendor ### At A Glance Mechanism GB-115 was designed as a retro-dipeptide analog of the beta turn of cholecystokinin tetrapeptide and acts as a low-affinity blocker of central cholecystokinin receptors (PMID: 17886432, PMID: 30295186). In mice and rats, activation of cholecystokinin tetrapeptide type 2 receptors… Half-Life Not established in humans; the published rat pharmacokinetic work reported an absolute oral bioavailability of 4.65 percent for the crystalline substance and did not report a terminal half-life (PMID: 18457023) Routes Oral Intraperitoneal injection (animal studies) Aerosol spray (form sold on the research chemical market) Potential Benefits Anxiolytic effect after oral administration in outbred mice, BALB/c mice and outbred rats in open field and elevated plus maze tests (PMID: 24130989) Antidepressant-like reduction of immobility time in the forced swim test in outbred, BALB/c and C57Bl/6 mice, weaker than amitriptyline (PMID: 21476266) Reduced average daily ethanol consumption and the alcohol deprivation effect in high-emotionality MR rats after 14 days of treatment (PMID: 27590755) Attenuated anxiety during benzodiazepine withdrawal in outbred and inbred rats, with partial normalization of striatal dopamine metabolites (PMID: 22238979) Reduced stress-related behavior and lowered the cortisol to DHEA-S ratio in four male rhesus monkeys under isolation, comparable to phenazepam (PMID: 39847298) Reported anxiolytic effect with improvements in attention parameters and reaction time in 31 patients with generalized anxiety disorder over 21 days (PMID: 31626171) ### Overview GB-115 is a synthetic dipeptide, N-(6-phenylhexanoyl)glycyl-L-tryptophan amide, designed at the Zakusov Research Institute of Pharmacology in Moscow. It belongs to a Russian program that builds short peptides as topological analogs of the active fragment of a regulatory peptide, the same approach that produced noopept and dilept. GB-115 is a retro-analog of the beta turn of cholecystokinin tetrapeptide, and conformational work identified a beta II turn as the structure responsible for its activity (PMID: 17886432, PMID: 24397028, PMID: 30295186). The stereochemistry matters. In the original series of analogs, the L-tryptophan compounds were anxiolytic and the D-tryptophan compounds anxiogenic, and GB-115 was selected as the L-tryptophan lead (PMID: 17886432). It acts as a low-affinity blocker of central cholecystokinin receptors. In mice and rats, activating cholecystokinin tetrapeptide type 2 receptors abolished its anti-anxiety effect and the compound prevented cholecystokinin-induced anxiety, while the alpha2 adrenoceptor antagonist yohimbine did not interact with it, which the authors read as a shared pharmacological target with cholecystokinin tetrapeptide (PMID: 23113301). The animal file is broad. Oral administration produced anxiolytic effects in outbred mice, BALB/c mice and outbred rats in open field and elevated plus maze tests (PMID: 24130989), antidepressant-like reduction of immobility in the forced swim test that was weaker than amitriptyline (PMID: 21476266), reduced average daily ethanol consumption and the alcohol deprivation effect in high-emotionality MR rats (PMID: 27590755), and reduced anxiety during benzodiazepine withdrawal in outbred and inbred rats (PMID: 22238979). A repeated theme is that the effect depends on the animal phenotype: strains with a passive response to emotional stress respond differently from active ones (PMID: 12910281). A study in four male rhesus monkeys under individual caging reported reduced stress-related behavior and a lower cortisol to DHEA-S ratio, comparable to phenazepam (PMID: 39847298). Safety and dependence data in animals are more complete than for most compounds sold this way. A preclinical package found no deaths after single oral administration at up to 6000 mg/kg in mice and 3500 mg/kg in rats, no irreversible organ changes over six months of oral administration in rats and rabbits, and no allergenic, immunotoxic or mutagenic activity and no effect on reproduction or offspring development (PMID: 20726348). After 30 days of daily administration to rats, stopping the compound produced no anxiety, aggression or convulsive signs, in contrast to diazepam withdrawal in the same experiment (PMID: 21899090). Oral bioavailability in rats was low at 4.65 percent for the crystalline substance, which is why later work compared micronized and reformulated versions (PMID: 18457023, PMID: 27017703). Human evidence is Russian and mostly unpublished in indexed journals. Thirty-one patients with generalized anxiety disorder were treated for 21 days, an effective daily dose was identified, and the authors described a fast anxiolytic effect with a stimulating component and favorable changes in attention parameters and reaction time (PMID: 31626171). That report does not describe randomization, blinding or a placebo arm in its published abstract. The Russian trial registry records that study as an open phase IIa pilot, followed by a double-blind, randomized, placebo-controlled multicenter trial sponsored by Valenta Pharm from April 2021 to December 2022, and the Russian product label cites two placebo-controlled trials of 168 and 220 patients, none of which is indexed in PubMed. On 29 December 2023 GB-115 was registered in Russia as the prescription tablet Rankvilon for anxiety states in neurasthenia and adjustment disorders. It has no FDA or EMA authorization, and the aerosol spray sold on the research chemical market is not the registered tablet and is a research-use-only compound in the US market. ### Potential Research Fields Anxiolytics Cholecystokinin receptor pharmacology Dipeptide drug design Anxiety and depression models ## Chemical Information IUPAC Name Not yet available CAS Number 678996-63-9 Molecular Formula C25H30N4O3 Molecular Mass 434.5 g/mol ![GB-115 molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/11281948/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/11281948) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications None established in humans. Mechanism-based: the compound blocks central cholecystokinin receptors (PMID: 23113301), so concurrent drugs acting on that system are an untested interaction. It potentiated morphine analgesia in mice through supraspinal opioid mechanisms (PMID: 18239806), which makes combination with opioids a mechanism-based concern. It also has immunomodulating activity in mice, stimulating macrophage phagocytosis and the humoral immune response (PMID: 19145294), and suppressed an experimental inflammatory response in rodents (PMID: 22235394), neither of which has been characterized in people. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $59.99 Best $/mg — Vendors 1 Listings 1 nasal\_spray [Sign in for alerts ](/auth) Form Allnasal\_spray Sort Price $/mg Vendor Vendor Product Form Qty Price $/mg Coupon ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK GB-115 aerosol spray, 10 mL nasal\_spray 10 mL aerosol spray ● In Stock $59.99 BEST — — [Buy](https://disguisedalpha.com/product/gb-115-aerosol-spray/?coupon=reddit) Get GB-115 Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. Current lowest: $59.99 [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with GB-115. [Sign in](/auth) Current low $59.99 as of Sep 7, 2026 7-day low $59.99 30-day low $59.99 30-day change — baseline building Tracking since Sep 7, 2026 · 1 data point ### Vendors Selling GB-115 [ ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) #### Disguised Alpha 1 listing · from $59.99 ](/vendor/disguised-alpha) How we score these vendors Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. [View Scorecard](/vendors/scorecard) ### Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Aniracetam Nootropics Approved (Italy) Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694). Preclinical View Profile ](/compound/aniracetam)[ ### Bemethyl (bemitil) Nootropics Approved (Russia) Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt. t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773) Preclinical View Profile ](/compound/bemethyl)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Cyclazodone Nootropics Preclinical Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. Preclinical View Profile ](/compound/cyclazodone)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa) [ View Full Dosage Guide → Protocols, calculator & safety for GB-115 ](/guides/dosage/gb-115) ### Best Price ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $59.99 [Buy Now](https://disguisedalpha.com/product/gb-115-aerosol-spray/?coupon=reddit) 1 vendors · 1 listings ### Research Score 30 0 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Half-Life Not established in humans; the published rat pharmacokinetic work reported an absolute oral bioavailability of 4.65 percent for the crystalline substance and did not report a terminal half-life (PMID: 18457023) Molecular Weight 434.5 g/mol Administration Oral, Intraperitoneal injection (animal studies), Aerosol spray (form sold on the research chemical market) CAS Number 678996-63-9 Trial Phase Approved (Russia) 0 [Full Dosage Guide](/guides/dosage/gb-115)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is GB-115 used for in research? GB-115 is a synthetic dipeptide, N-(6-phenylhexanoyl)glycyl-L-tryptophan amide, designed at the Zakusov Research Institute of Pharmacology in Moscow. It belongs to a Russian program that builds short peptides as topological analogs of the active fragment of a regulatory peptide, the same approach that produced noopept and dilept. GB-115 is a retro-analog of the beta turn of cholecystokinin tetrapeptide, and conformational work identified a beta II turn as the structure responsible for its activity (PMID: 17886432, PMID: 24397028, PMID: 30295186). The stereochemistry matters. In the original series of analogs, the L-tryptophan compounds were anxiolytic and the D-tryptophan compounds anxiogenic, and GB-115 was selected as the L-tryptophan lead (PMID: 17886432). It acts as a low-affinity blocker of central cholecystokinin receptors. In mice and rats, activating cholecystokinin tetrapeptide type 2 receptors abolished its anti-anxiety effect and the compound prevented cholecystokinin-induced anxiety, while the alpha2 adrenoceptor antagonist yohimbine did not interact with it, which the authors read as a shared pharmacological target with cholecystokinin tetrapeptide (PMID: 23113301). The animal file is broad. Oral administration produced anxiolytic effects in outbred mice, BALB/c mice and outbred rats in open field and elevated plus maze tests (PMID: 24130989), antidepressant-like reduction of immobility in the forced swim test that was weaker than amitriptyline (PMID: 21476266), reduced average daily ethanol consumption and the alcohol deprivation effect in high-emotionality MR rats (PMID: 27590755), and reduced anxiety during benzodiazepine withdrawal in outbred and inbred rats (PMID: 22238979). A repeated theme is that the effect depends on the animal phenotype: strains with a passive response to emotional stress respond differently from active ones (PMID: 12910281). A study in four male rhesus monkeys under individual caging reported reduced stress-related behavior and a lower cortisol to DHEA-S ratio, comparable to phenazepam (PMID: 39847298). Safety and dependence data in animals are more complete than for most compounds sold this way. A preclinical package found no deaths after single oral administration at up to 6000 mg/kg in mice and 3500 mg/kg in rats, no irreversible organ changes over six months of oral administration in rats and rabbits, and no allergenic, immunotoxic or mutagenic activity and no effect on reproduction or offspring development (PMID: 20726348). After 30 days of daily administration to rats, stopping the compound produced no anxiety, aggression or convulsive signs, in contrast to diazepam withdrawal in the same experiment (PMID: 21899090). Oral bioavailability in rats was low at 4.65 percent for the crystalline substance, which is why later work compared micronized and reformulated versions (PMID: 18457023, PMID: 27017703). Human evidence is Russian and mostly unpublished in indexed journals. Thirty-one patients with generalized anxiety disorder were treated for 21 days, an effective daily dose was identified, and the authors described a fast anxiolytic effect with a stimulating component and favorable changes in attention parameters and reaction time (PMID: 31626171). That report does not describe randomization, blinding or a placebo arm in its published abstract. The Russian trial registry records that study as an open phase IIa pilot, followed by a double-blind, randomized, placebo-controlled multicenter trial sponsored by Valenta Pharm from April 2021 to December 2022, and the Russian product label cites two placebo-controlled trials of 168 and 220 patients, none of which is indexed in PubMed. On 29 December 2023 GB-115 was registered in Russia as the prescription tablet Rankvilon for anxiety states in neurasthenia and adjustment disorders. It has no FDA or EMA authorization, and the aerosol spray sold on the research chemical market is not the registered tablet and is a research-use-only compound in the US market. What forms does GB-115 come in? GB-115 is available in nasal\_spray form. How much does GB-115 cost? Prices start at $59.99 across 1 verified vendor. How do I compare GB-115 vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Aniracetam Nootropics Approved (Italy) Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694). Preclinical View Profile ](/compound/aniracetam)[ ### Bemethyl (bemitil) Nootropics Approved (Russia) Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt. t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773) Preclinical View Profile ](/compound/bemethyl)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Cyclazodone Nootropics Preclinical Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. Preclinical View Profile ](/compound/cyclazodone)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-gb-115) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋